vs
First Bancorp, Inc（FNLC）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是First Bancorp, Inc的1.2倍（$30.3M vs $25.8M），First Bancorp, Inc净利率更高（39.4% vs -221.3%，领先260.7%），REGENXBIO Inc.同比增速更快（43.0% vs 17.5%），First Bancorp, Inc自由现金流更多（$34.6M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 18.1%）
第一银行公司（First Bancorp, Inc）是一家银行控股公司，其核心业务通过总部位于康涅狄格州斯坦福的爱国者国家银行（Patriot Bank NA）开展，相关 banking 业务也以PNBK代码在纳斯达克挂牌交易。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
FNLC vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.2倍
$25.8M
营收增速更快
RGNX
高出25.5%
17.5%
净利率更高
FNLC
高出260.7%
-221.3%
自由现金流更多
FNLC
多$87.4M
$-52.8M
两年增速更快
RGNX
近两年复合增速
18.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $25.8M | $30.3M |
| 净利润 | $10.2M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 48.1% | -190.0% |
| 净利率 | 39.4% | -221.3% |
| 营收同比 | 17.5% | 43.0% |
| 净利润同比 | 39.7% | -31.2% |
| 每股收益（稀释后） | $0.91 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FNLCRGNX
| Q4 25 | $25.8M | $30.3M | ||
| Q3 25 | $24.5M | $29.7M | ||
| Q2 25 | $22.5M | $21.4M | ||
| Q1 25 | $21.8M | $89.0M | ||
| Q4 24 | $22.0M | $21.2M | ||
| Q3 24 | $20.5M | $24.2M | ||
| Q2 24 | $19.2M | $22.3M | ||
| Q1 24 | $18.5M | $15.6M |
净利润FNLCRGNX
| Q4 25 | $10.2M | $-67.1M | ||
| Q3 25 | $9.1M | $-61.9M | ||
| Q2 25 | $8.1M | $-70.9M | ||
| Q1 25 | $7.1M | $6.1M | ||
| Q4 24 | $7.3M | $-51.2M | ||
| Q3 24 | $7.6M | $-59.6M | ||
| Q2 24 | $6.2M | $-53.0M | ||
| Q1 24 | $6.0M | $-63.3M |
毛利率FNLCRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率FNLCRGNX
| Q4 25 | 48.1% | -190.0% | ||
| Q3 25 | 45.2% | -176.3% | ||
| Q2 25 | 43.7% | -296.3% | ||
| Q1 25 | 39.3% | 13.6% | ||
| Q4 24 | 39.5% | -242.1% | ||
| Q3 24 | 44.6% | -256.6% | ||
| Q2 24 | 38.8% | -251.3% | ||
| Q1 24 | 39.3% | -408.8% |
净利率FNLCRGNX
| Q4 25 | 39.4% | -221.3% | ||
| Q3 25 | 37.0% | -208.3% | ||
| Q2 25 | 35.8% | -331.8% | ||
| Q1 25 | 32.5% | 6.8% | ||
| Q4 24 | 33.1% | -241.3% | ||
| Q3 24 | 36.9% | -246.3% | ||
| Q2 24 | 32.1% | -237.7% | ||
| Q1 24 | 32.5% | -405.4% |
每股收益（稀释后）FNLCRGNX
| Q4 25 | $0.91 | $-1.30 | ||
| Q3 25 | $0.81 | $-1.20 | ||
| Q2 25 | $0.72 | $-1.38 | ||
| Q1 25 | $0.63 | $0.12 | ||
| Q4 24 | $0.66 | $-0.99 | ||
| Q3 24 | $0.68 | $-1.17 | ||
| Q2 24 | $0.55 | $-1.05 | ||
| Q1 24 | $0.54 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $230.1M |
| 总债务越低越好 | $95.5M | — |
| 股东权益账面价值 | $283.1M | $102.7M |
| 总资产 | $3.2B | $453.0M |
| 负债/权益比越低杠杆越低 | 0.34× | — |
8季度趋势，按日历期对齐
现金及短期投资FNLCRGNX
| Q4 25 | — | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M | ||
| Q1 24 | — | $338.7M |
总债务FNLCRGNX
| Q4 25 | $95.5M | — | ||
| Q3 25 | $95.5M | — | ||
| Q2 25 | $95.0M | — | ||
| Q1 25 | $70.0M | — | ||
| Q4 24 | $95.0M | — | ||
| Q3 24 | $95.0M | — | ||
| Q2 24 | $70.0M | — | ||
| Q1 24 | $70.0M | — |
股东权益FNLCRGNX
| Q4 25 | $283.1M | $102.7M | ||
| Q3 25 | $274.6M | $161.5M | ||
| Q2 25 | $265.5M | $213.7M | ||
| Q1 25 | $259.7M | $274.2M | ||
| Q4 24 | $252.5M | $259.7M | ||
| Q3 24 | $256.8M | $301.4M | ||
| Q2 24 | $244.7M | $348.3M | ||
| Q1 24 | $242.6M | $390.7M |
总资产FNLCRGNX
| Q4 25 | $3.2B | $453.0M | ||
| Q3 25 | $3.2B | $525.2M | ||
| Q2 25 | $3.2B | $581.0M | ||
| Q1 25 | $3.2B | $490.9M | ||
| Q4 24 | $3.2B | $466.0M | ||
| Q3 24 | $3.1B | $519.1M | ||
| Q2 24 | $3.1B | $569.4M | ||
| Q1 24 | $3.0B | $629.2M |
负债/权益比FNLCRGNX
| Q4 25 | 0.34× | — | ||
| Q3 25 | 0.35× | — | ||
| Q2 25 | 0.36× | — | ||
| Q1 25 | 0.27× | — | ||
| Q4 24 | 0.38× | — | ||
| Q3 24 | 0.37× | — | ||
| Q2 24 | 0.29× | — | ||
| Q1 24 | 0.29× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $37.8M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $34.6M | $-52.8M |
| 自由现金流率自由现金流/营收 | 133.9% | -174.0% |
| 资本支出强度资本支出/营收 | 12.5% | 1.7% |
| 现金转化率经营现金流/净利润 | 3.72× | — |
| 过去12个月自由现金流最近4个季度 | $55.3M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流FNLCRGNX
| Q4 25 | $37.8M | $-52.3M | ||
| Q3 25 | $12.9M | $-56.0M | ||
| Q2 25 | $7.4M | $-49.3M | ||
| Q1 25 | $2.2M | $33.6M | ||
| Q4 24 | $26.0M | $-31.6M | ||
| Q3 24 | $9.8M | $-40.5M | ||
| Q2 24 | $6.4M | $-45.5M | ||
| Q1 24 | $-1.5M | $-55.5M |
自由现金流FNLCRGNX
| Q4 25 | $34.6M | $-52.8M | ||
| Q3 25 | $12.6M | $-56.5M | ||
| Q2 25 | $7.2M | $-49.7M | ||
| Q1 25 | $828.0K | $32.6M | ||
| Q4 24 | $24.6M | $-32.7M | ||
| Q3 24 | $9.6M | $-40.9M | ||
| Q2 24 | $6.3M | $-46.0M | ||
| Q1 24 | $-1.8M | $-56.0M |
自由现金流率FNLCRGNX
| Q4 25 | 133.9% | -174.0% | ||
| Q3 25 | 51.4% | -189.9% | ||
| Q2 25 | 32.1% | -232.8% | ||
| Q1 25 | 3.8% | 36.6% | ||
| Q4 24 | 111.7% | -154.2% | ||
| Q3 24 | 47.0% | -168.9% | ||
| Q2 24 | 32.9% | -206.2% | ||
| Q1 24 | -9.8% | -358.5% |
资本支出强度FNLCRGNX
| Q4 25 | 12.5% | 1.7% | ||
| Q3 25 | 1.2% | 1.7% | ||
| Q2 25 | 0.6% | 1.8% | ||
| Q1 25 | 6.2% | 1.2% | ||
| Q4 24 | 6.7% | 5.1% | ||
| Q3 24 | 0.5% | 1.3% | ||
| Q2 24 | 0.3% | 2.1% | ||
| Q1 24 | 1.8% | 3.6% |
现金转化率FNLCRGNX
| Q4 25 | 3.72× | — | ||
| Q3 25 | 1.42× | — | ||
| Q2 25 | 0.91× | — | ||
| Q1 25 | 0.31× | 5.53× | ||
| Q4 24 | 3.58× | — | ||
| Q3 24 | 1.29× | — | ||
| Q2 24 | 1.03× | — | ||
| Q1 24 | -0.25× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FNLC
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
